Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Oligodendroglioma
Status:
Terminated
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Current therapies for adult recurrent/progressive oligodendrogliomas provide very
limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest
that it may prove beneficial in the treatment of childhood brain tumors.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on adult recurrent/progressive oligodendrogliomas.